Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

RSS icon
doctor with overweight patient who may be treated with TAVR or surgery

Weight loss drug semaglutide could boost heart health of up to 93M patients in US alone

Researchers have recently determined that the medication, originally developed to treat diabetes, can contribute to weight loss and reduce a patient's MACE risk by up to 20%. 

semaglutide wegovy Novo Nordisk major adverse cardiovascular events

Weight loss drug semaglutide reduces risk of adverse cardiovascular events by 20% among overweight, obese patients

Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.

Hari Naidu, MD, explains that inconsistent diagnostic imaging and how it is reported has likely led to a major underdiagnosis of HCM. #ASE #ASE2023 #HCM

Why hypertrophic cardiomyopathy may be widely underdiagnosed

One expert believes the lack of standardization for how diagnostic imaging in conducted and reported has led to a major underdiagnosis of HCM.

Lisa Salberg, CEO of the Hypertrophic Cardiomyopathy Association (HCMA) explains how the group has helped improve HCM patient care.

Hypertrophic Cardiomyopathy Association has helped advance HCM care

The Hypertrophic Cardiomyopathy Association (HCMA) has helped guide and advance HCM care not only for patients, but also for hospitals and physicians. 

Peter Libby, MD, explains how infections cause heart attacks. This came out of research taking a close look at COVID, but the inflammation from any infection may cause increased inflammation of coronary plaques that cause heart attacks. #COVID #COVID19

Do infections cause heart attacks? Lessons from COVID

COVID-19 opened the eyes of many cardiology researchers that infections may promote inflammation in atherosclerotic plaques, leading to cardiac events.

Matt Martinez, MD, Morristown Medical Center HCM program, explains how hypertrophic cardiomyopathy patient management is changing.

Exercise plays a key part in HCM management

Matthew Martinez, MD, detailed the many ways HCM care management is changing during an exclusive interview at ASE 2023.

doctor with overweight patient who may be treated with TAVR or surgery

TAVR vs. surgery among obese patients: What cardiologists need to know

Researchers tracked data from nearly 38,000 obese patients who underwent TAVR or SAVR, sharing their findings in a new meta-analysis. 

Eli Lilly to acquire private equity-backed drugmaker for up to $1.9B

Versanis, founded in 2021 by a venture capital firm, is primarily known as the company behind the obesity drug bimagrumab.

Displaying 153 - 160 of 1153

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.